ADHD Drug Cardiac Events, COX-2s Are Topics For Drug Safety Committee Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies to determine risk of cardiovascular adverse outcomes with attention deficit/hyperactivity disorder drugs will be discussed at Feb. 9-10 meeting. Risk management programs for isotretinoin products also on the agenda.
You may also be interested in...
Cardiac, Neuropsychiatric Events With ADHD Drugs To Be Discussed By Pediatric Committee
FDA's Pediatric Advisory Committee will address neuropsychiatric and cardiovascular events possibly related to attention deficit/hyperactivity disorder medications at a March 22 meeting
Cephalon Sparlon For ADHD To Get Psychopharm Committee Review
The March 23 review of the new indication for modafinil, currently marketed as Provigil for narcolepsy, will likely focus on safety differences compared to other ADHD drugs.
Cardiac, Neuropsychiatric Events With ADHD Drugs To Be Discussed By Pediatric Committee
FDA's Pediatric Advisory Committee will address neuropsychiatric and cardiovascular events possibly related to attention deficit/hyperactivity disorder medications at a March 22 meeting